Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA289912 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Transcriptional profiling of HEK293T cells following treatment with a small molecule inhibitor of catalytic activity of the G9a lysine methyltransferase (UNC0638, 1 micromolar, 48 hours), or siRNA against WIZ or G9a (72 hours treatment).
2015-07-15 | GSE70914 | GEO
Project description:G9a and GLP lysine methyltransferases form a heterodimeric complex that is responsible for the bulk of cellular mono- and di-methylation on histone H3 lysine 9 (H3K9me1/me2). Widely Interspaced Zinc finger (WIZ) associates with the G9a/GLP protein complex, but its role in lysine methylation is poorly defined. Here, we show that WIZ regulates global H3K9me2 levels through a mechanism that involves retention of G9a on chromatin. We also show that WIZ-mediated chromatin loss of G9a/GLP results in altered gene expression and protein-protein interactions that are distinguishable from that of using a molecule-induced enzymatic inhibitor towards G9a/GLP – thus providing evidence that the G9a/GLP/WIZ complex has unique functions when bound to chromatin that are independent of the H3K9me2 mark DMSO, UNC0638, NS, and siWIZ treatments to HEK293T cells, assessing G9a and H3K9me2 localization, each performed in duplicate, plus one input control for each cell condition. 30 samples total.
2015-09-03 | E-GEOD-67317 | biostudies-arrayexpress
Project description:G9a and GLP lysine methyltransferases form a heterodimeric complex that is responsible for the bulk of cellular mono- and di-methylation on histone H3 lysine 9 (H3K9me1/me2). Widely Interspaced Zinc finger (WIZ) associates with the G9a/GLP protein complex, but its role in lysine methylation is poorly defined. Here, we show that WIZ regulates global H3K9me2 levels through a mechanism that involves retention of G9a on chromatin. We also show that WIZ-mediated chromatin loss of G9a/GLP results in altered gene expression and protein-protein interactions that are distinguishable from that of using a molecule-induced enzymatic inhibitor towards G9a/GLP – thus providing evidence that the G9a/GLP/WIZ complex has unique functions when bound to chromatin that are independent of the H3K9me2 mark
2015-09-03 | GSE67317 | GEO
Project description:Cholangiocarcinogenesis involves epigenetic abnormalities of great relevance. Both the histone methyltransferase G9A and the DNA methyltransferase DNMT1 are overexpressed in this tumor. We used microarrays to evaluate the global programme of gene expression in the human CCA cell line EGI-1 treated with CM272. This molecule is an epigenetic inhibitor that simultaneously targets the methyltransferase activities of G9a and DNMT1. EGI-1 cells treatment with CM272 (200nM) or vehicle (0.01% DMSO) for 48 hours.
2020-11-01 | GSE144183 | GEO
Project description:We profiled chromatin accessibility across the genome of HSPCs treated with either a small molecule inhibitor of G9a/GLP or DMSO. We observed that chromatin accessibility is dramatically altered at the regions of H3K9me2 nucleation. We have characterized the regions of H3K9me2 nucleation, revealing that H3K9me2 is nucleated in HSPCs at CpG islands (CGIs) and CGI-like sequences across the genome. Our analysis furthermore revealed a bias of H3K9me2 nucleation towards regions with low rates of C->T deamination, which typically lack DNA methylation. Lastly we examined the interaction of H3K9me2 and DNA methylation and determined that chromatin accessibility changes upon loss of H3K9me2 are dependent on the presence of DNA methylation. Examination of chromatin remodeling with FAIRE-seq in HSPCs treated with either a small molecule inhibitor of G9a/GLP or DMSO
2014-09-25 | E-GEOD-59749 | biostudies-arrayexpress
Project description:We used mass spectrometry-based proteomics to unravel anaplastic lymphoma kinase (ALK) signaling in the ALK and MYCN amplified neuroblastoma cell line, NB1. We specifically measured the ALK phosphoproteome upon siRNA depletion of ALK and upon ALK inhibition using the ALK-targeting small-molecule inhibitor lorlatinib. For quantitative phosphoproteomics we used a tandem mass tag (TMT)-based approach. Conditions for the TMT 11-plex setup is specified below. For each siRNA depletion experiment, NB1 cells were treated with siRNA (80 nM; as specified below) for 48 hours prior to stimulation with 0.1% DMSO for 30 minutes. For inhibitor treatment, NB1 cells were treated for 30 minutes with either 10 microM or 10 nM lorlatinib. The experimental treatment conditions and TMT11-plex labeling are specified below: 126: siControl replicate 1, 0.1% DMSO 127N: siControl replicate 2, 0.1% DMSO 127C: siControl replicate 3, 0.1% DMSO 128N: siALK sequence 1, 0.1% DMSO 128C: siALK sequence 2, 0.1% DMSO 129N: siALK mix of sequence 1 and 2, 0.1% DMSO 129C: 10 microM lorlatinib replicate 1 130N: 10 microM lorlatinib replicate 2 130C: 10 microM lorlatinib replicate 3 131N: 10 nM lorlatinib replicate 1 131C: 10 nM lorlatinib replicate 2
2018-11-21 | PXD009477 | Pride
Project description:PMVEC treated with scrambled siRNA, or siRNA to CYP1B1 are treated with vehicle, 1uM E2, or 1uM 16aOHE
2024-02-01 | GSE166006 | GEO
Project description:The transcriptional profile of Escherichia coli O157 treated with small molecule inhibitors of type III secretion was determined. Four variations of the small molecule inhibitor were assessed for global changes in transcription by treating cells with 20uM of inhibitor or an equivalent volume of DMSO (inhibitor solvent). Keywords: treatment, dose, Cy3, Cy5, 2-colour
2009-08-11 | GSE10319 | GEO
Project description:Lysine methylation of histone proteins regulates chromatin dynamics and plays important roles in diverse physiological and pathological processes. However, beyond histone proteins, the proteome-wide extent of lysine methylation is largely unknown. We have developed the naturally occurring MBT domain repeats of L3MBTL1 (3xMBT) to serve as a universal affinity reagent for detecting, enriching, and identifying proteins carrying a mono- or dimethylated lysine. The domain is broadly specific for methylated lysine ("pan-specific") and can be applied to any biological system. In experiments using two different instruments (experiment 1 - Orbitrap Elite, experiment 2 - Orbitrap Velos) we have used SILAC to compare proteins captured by 3xMBT to proteins captured by the D355N mutant, which does not bind methylated lysine. Data was analyzed using MaxQuant version 1.3.0.5 using default parameters except that mono and di-methylated lysine were included as variable modifications and modification-specific false discovery rate was set to 10%. Several hundred proteins are specifically enriched by 3xMBT and we have directly detected lysine methylation on about two dozen. We have also used our approach to identify candidate in-cell substrates of G9a and the related methyltransferase GLP. Three-way SILAC was used to compare methylated proteins between cells treated with UNC0638, a specific inhibitor of G9a and GLP, and cells treated with vehicle control. We find reduced capture of the known G9a substrates WIZ and ACIN1, as well as identifying DNA ligase 1 as a potential target for G9a/GLP. Together, our results demonstrate a powerful new approach for global and quantitative analysis of methylated lysine, and they represent the first systems biology understanding of lysine methylation.
2013-11-11 | PXD000361 | Pride
Project description:The G9a mediates mono- and dimethylation of Lys9 of histone H3 at specific gene loci, which is associated with transcriptional repression. ZNF644 and WIZ contain multiple zinc finger motifs that recognize consensus DNA sequences.
2015-03-20 | GSE62616 | GEO